PDE6A

Across TCGA pan-cancer cohorts, PDE6A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDE6A data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PDE6A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDE6A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, LGG, and PRAD are the cancer types where PDE6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
LGG	OS	Median	All	0.204	0.799	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
UCEC	DFS	Median	All	0.952	0.828	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDE6A–SCLC (OS)

Open the SCLC breakdown →